News

Travoprost XR Phase 2 Data Shows 9-Month Duration Of Action After A Single Dose in Glaucoma Patients Envisia Therapeutics released an interim analysis of its ENV515 (travoprost XR) phase 2 trial in glaucoma patients showi...